NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 6 percent year over year, driven in part by growth in its sample-to-answer molecular product sales.

For the three months ended March 31, the firm reported revenues of $82.7 million, up from $77.8 million a year ago, and beating the consensus Wall Street estimate of $80.5 million.